Vanda Pharmaceuticals Initiated at Overweight by Cantor Fitzgerald

Vanda Pharmaceuticals Initiated at Overweight by Cantor

Dow JonesJul 11 07:37 ET

Vanda Pharma Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 105.61% Cantor Fitzgerald → $11 Initiates Coverage On → Overweight 02/25/2022 124.3%

BenzingaJul 11 07:26 ET

Cantor Fitzgerald Initiates Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Announces Target Price $11

Cantor Fitzgerald analyst Charles Duncan initiates coverage on $Vanda Pharmaceuticals(VNDA.US)$ with a buy rating, and sets the target price at $11.According to TipRanks data, the analyst has a

Moomoo NewsJul 11 06:35 ET · Ratings

Vanda Will Request Relief From Court That Includes Order Requiring Defendants to Discontinue Marketing Generic Versions of HETLIOZ >VNDA

Vanda Will Request Relief From Court That Includes Order Requiring Defendants to Discontinue Marketing Generic Versions of HETLIOZ >VNDA

Dow JonesJul 1 08:09 ET

Vanda Intends to Proceed With Discovery in the Case to Continue Pursuing Its Claims >VNDA

Vanda Intends to Proceed With Discovery in the Case to Continue Pursuing Its Claims >VNDA

Dow JonesJul 1 08:08 ET

Vanda: Court Concluded Issues of Patentability Weren't Same as Those Resolved in Prior Patent-Infringement Litigation Between Parties >VNDA

Vanda: Court Concluded Issues of Patentability Weren't Same as Those Resolved in Prior Patent-Infringement Litigation Between Parties >VNDA

Dow JonesJul 1 08:08 ET